Conversion Chemotherapy for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine?
Year: 2025
Type: article
Language: en
Topic: Pancreatic and Hepatic Oncology Research
Authors and affiliations:
raw_author_name: Kaibo Guo
raw_affiliation_strings: Kaibo Guo, MD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China; Jiamin Lu, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China; Xinlei Zhou, MD, The Third Clinical Medical School, the Rehabilitation Medical School, Zhejiang Chinese Medical University, Hangzhou, China; and Song Zheng, PhD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China
Kaibo Guo, MD, Department of Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China, Jiamin Lu, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China, Xinlei Zhou, MD, The Third Clinical Medical School, the Rehabilitation Medical School, Zhejiang Chinese Medical University, Hangzhou, China, Song Zheng, PhD, Department of Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China
raw_author_name: Jiamin Lu
raw_affiliation_strings: Kaibo Guo, MD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China; Jiamin Lu, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China; Xinlei Zhou, MD, The Third Clinical Medical School, the Rehabilitation Medical School, Zhejiang Chinese Medical University, Hangzhou, China; and Song Zheng, PhD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China
Kaibo Guo, MD, Department of Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China, Jiamin Lu, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China, Xinlei Zhou, MD, The Third Clinical Medical School, the Rehabilitation Medical School, Zhejiang Chinese Medical University, Hangzhou, China, Song Zheng, PhD, Department of Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China
raw_author_name: Xinlei Zhou
raw_affiliation_strings: Kaibo Guo, MD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China; Jiamin Lu, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China; Xinlei Zhou, MD, The Third Clinical Medical School, the Rehabilitation Medical School, Zhejiang Chinese Medical University, Hangzhou, China; and Song Zheng, PhD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China
Kaibo Guo, MD, Department of Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China, Jiamin Lu, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China, Xinlei Zhou, MD, The Third Clinical Medical School, the Rehabilitation Medical School, Zhejiang Chinese Medical University, Hangzhou, China, Song Zheng, PhD, Department of Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China
raw_author_name: Song Zheng
raw_affiliation_strings: Kaibo Guo, MD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China; Jiamin Lu, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China; Xinlei Zhou, MD, The Third Clinical Medical School, the Rehabilitation Medical School, Zhejiang Chinese Medical University, Hangzhou, China; and Song Zheng, PhD, Department of Oncology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China
Kaibo Guo, MD, Department of Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China, Jiamin Lu, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China, Xinlei Zhou, MD, The Third Clinical Medical School, the Rehabilitation Medical School, Zhejiang Chinese Medical University, Hangzhou, China, Song Zheng, PhD, Department of Oncology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China